The AZD1222 coronavirus vaccine candidate, formerly known as ChAdOx1 nCoV-19, is made from a virus (ChAdOx1), which is a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees, that has been genetically changed so that it is impossible for it to grow in humans.

Genetic material has been added to the ChAdOx1 construct, which is used to make proteins from the SARS-CoV-2 coronavirus called Spike glycoprotein (S). This protein is usually found on the surface of SARS-CoV-2 and plays an essential role in the infection pathway of the SARS-CoV-2 virus.

Investigational ChAdOx1 nCoV-19 vaccine protects monkeys against COVID-19 pneumonia

The phase II part of the study involves expanding the age range of people the vaccine is assessed in, to include a small number of older adults and children:

• Aged 56-69

• Aged over 70

• Aged between 5-12 years

For these groups, researchers will be assessing the immune response to the vaccine in people of different ages, to find out if there is variation in how well the immune system responds in older people or children.

The phase III part of the study involves assessing how the vaccine works in a large number of people over the age of 18. This group will assess how well the vaccine works to prevent people from becoming infected and unwell with COVID-19.

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit

http://www.ox.ac.uk/news/2020-06-14-astrazeneca-supply-europe-400-million-doses-oxford-university-s-vaccine-no-profit

More Amal Alhasan's questions See All
Similar questions and discussions